Wall Street Zen Downgrades Humacyte (NASDAQ:HUMA) to Strong Sell

Humacyte (NASDAQ:HUMA) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday.

Several other research firms also recently issued reports on HUMA. Benchmark reduced their price target on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a report on Wednesday, July 8th. BTIG Research reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Humacyte in a research note on Wednesday. HC Wainwright lifted their price objective on shares of Humacyte from $3.00 to $4.00 and gave the company a “buy” rating in a report on Thursday, June 11th. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Tuesday, April 28th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $6.11.

Humacyte Price Performance

HUMA stock opened at $0.60 on Friday. The stock’s 50 day simple moving average is $0.78 and its 200 day simple moving average is $0.90. The company has a market cap of $163.08 million, a P/E ratio of -1.23 and a beta of 2.54. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21. Humacyte has a fifty-two week low of $0.53 and a fifty-two week high of $2.55.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). The firm had revenue of $0.41 million during the quarter, compared to analyst estimates of $1.04 million. Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. On average, research analysts expect that Humacyte will post -0.38 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Kathleen Sebelius acquired 56,818 shares of the company’s stock in a transaction on Tuesday, May 19th. The shares were acquired at an average cost of $0.88 per share, for a total transaction of $49,999.84. Following the purchase, the director owned 148,025 shares in the company, valued at approximately $130,262. The trade was a 62.30% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 3.10% of the company’s stock.

Institutional Trading of Humacyte

Several institutional investors have recently made changes to their positions in HUMA. Ieq Capital LLC purchased a new stake in shares of Humacyte in the second quarter valued at about $218,000. LaSalle St. Investment Advisors LLC purchased a new position in Humacyte during the second quarter worth about $89,000. BlackRock Inc. purchased a new position in Humacyte during the second quarter worth about $3,777,000. Wealth Effects LLC bought a new stake in Humacyte in the 2nd quarter worth about $542,000. Finally, Bank of New York Mellon Corp bought a new stake in Humacyte in the 2nd quarter worth about $44,000. Institutional investors own 44.71% of the company’s stock.

Key Stories Impacting Humacyte

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $4.00 price target, substantially above Humacyte’s recent trading level. The firm still projects a transition to positive earnings in FY2029 and FY2030, at $0.09 and $0.31 per share, respectively.
• Neutral Sentiment: Humacyte’s shares remain near their 52-week low, while trading volume has been significantly above average. That combination highlights elevated investor interest but also substantial volatility and uncertainty around the company’s outlook.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to a loss of $0.46 from $0.37 and cut its FY2027 estimate to a loss of $0.30 from $0.26. It also lowered quarterly estimates for Q3 and Q4 2026 and Q3 and Q4 2027, indicating expectations for wider near-term losses.
• Negative Sentiment: The analyst lowered longer-term estimates as well, cutting FY2029 EPS to $0.09 from $0.20 and FY2030 EPS to $0.31 from $0.50. Although profitability is still projected, the reduced forecasts weaken the valuation case and may pressure the stock. Benchmark Issues Pessimistic Forecast for Humacyte Stock Price
• Negative Sentiment: Wall Street Zen downgraded Humacyte to Strong Sell, adding to the negative sentiment surrounding the stock. Humacyte Lowered to Strong Sell Rating by Wall Street Zen

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.